Literature DB >> 22618230

IL-7 splicing variant IL-7δ5 induces human breast cancer cell proliferation via activation of PI3K/Akt pathway.

Deshun Pan1, Bing Liu, Xiaobao Jin, Jiayong Zhu.   

Abstract

Various tumor cells express interleukin 7 (IL-7) and IL-7 variants. IL-7 has been confirmed to stimulate solid tumor cell proliferation. However, the effect of IL-7 variants on tumor cell proliferation remains unclear. In this study, we evaluated the role of IL-7δ5 (an IL-7 variant lacking exon 5) on proliferation and cell cycle progression of human MDA-MB-231 and MCF-7 breast cancer cells. The results showed that IL-7δ5 promoted cell proliferation and cell cycle progression from G1 phase to G2/M phase, associated with upregulation of cyclin D1 expression and the downregulation of p27(kip1) expression. Mechanistically, we found that IL-7δ5 induced the activation of Akt. Inhibition of PI3K/Akt pathway by LY294002 reversed the proliferation and cell cycle progression of MDA-MB-231 and MCF-7 cells induced by IL-7δ5. In conclusion, our findings demonstrate that IL-7δ5 variant induces human breast cancer cell proliferation and cell cycle progression via activation of PI3K/Akt pathway. Thus, IL-7δ5 may be a potential target for human breast cancer therapeutics intervention.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22618230     DOI: 10.1016/j.bbrc.2012.05.070

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

2.  IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.

Authors:  Jie Yang; Zhi Zeng; Yuyu Peng; Jianhua Chen; Ling Pan; Deshun Pan
Journal:  Histochem Cell Biol       Date:  2014-04-26       Impact factor: 4.304

3.  The role of interleukin‑7 serum level as biological marker in breast cancer: a cross‑sectional, observational, and analytical study.

Authors:  Faton Sermaxhaj; Natalija Dedić Plavetić; Ugur Gozalan; Ana Kulić; Ljubica Radmilović Varga; Marina Popović; Slavica Sović; Davor Mijatović; Besim Sermaxhaj; Mentor Sopjani
Journal:  World J Surg Oncol       Date:  2022-07-06       Impact factor: 3.253

4.  The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines.

Authors:  Ying-Ying Wang; Xiao-Ling Gu; Chao Wang; Hua Wang; Qi-Chao Ni; Chun-Hui Zhang; Xia-Fei Yu; Li-Yi Yang; Zhi-Xian He; Guo-Xin Mao; Shu-Yun Yang
Journal:  Tumour Biol       Date:  2016-01-25

5.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Loss of GATA4 C-Terminus by p.S335X Mutation Modulates Coronary Artery Vascular Smooth Muscle Cell Phenotype.

Authors:  Ting-Yan Yu; Xin-Xin Chen; Qing-Wen Liu; Fang-Fang Ma; Hong-Lang Huang; Lei Zhou; Wei Zhang
Journal:  Mediators Inflamm       Date:  2021-09-11       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.